What's next for Ebos after the end of that Chemist Warehouse contract

What's next for Ebos after the end of that Chemist Warehouse contract
CEO John Cullity says there isn't double-digit growth to be found in animal or healthcare in Australasia. (Image: Ebos)
Rebecca Stevenson
Ebos chief executive John Cullity says the firm must hunt outside of Australasia for double-digit growth. The dual-listed healthcare and pharmaceutical marketer and wholesaler was looking for growth outside its traditional powerhouse pharmaceutical business, Cullity said. He said Ebos’s pharmacy business in NZ and Australia was solid and stable but had relatively low growth. “Double-digit growth rates are going to be very hard, so we need to broaden the group's base of earnings outside of Australia and New Zealand...

More Markets

NZ sharemarket down ahead of big US election
Markets Market close

NZ sharemarket down ahead of big US election

The S&P/NZX 50 Index closed at 12,648.07, down 46.77 points or 0.37%.

CMC markets seeks NZX accreditation
Markets

CMC markets seeks NZX accreditation

The Australian firm with over a million retail investors wants to be listed here too.

Vista board unlikely to be spilt, says Craigs
Markets

Vista board unlikely to be spilt, says Craigs

The board of NZX, ASX listed cinema company Vista likely to remain despite calls contrary

SkyCity to put compliance ahead of profits
Markets

SkyCity to put compliance ahead of profits

Tough market conditions and regulatory issues still challenges, casino operator says.